The Competition Commission of India’s (CCI) recent prescription to ensure that markets work towards affordable healthcare may have stirred the pot, reigniting debate around certain staple industry practices that the regulator believes could “choke” competition and are detrimental to consumer interest.
Some pharmaceutical industry experts, at the outset, say that the CCI may have overstepped its brief, getting into policy- and quality-related territory.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?